Revenue segments as reported by the company.

Premiums

Services

Investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefits

Operating costs

Depreciation and amortization

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Humana

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance. The Healthcare Services segment offers services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics to other Humana businesses, as well as external health plan members, and other employers. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humana exceeds earnings expectations, focuses on value-based care growth

Humana's strong financial performance and growth in value-based care position the company well for future success. Addressing audit error rates, uncertainties around RADV, and managing costs are key challenges. Opportunities in recruiting, revenue growth, and strategic partnerships offer avenues for further growth.

Humana exceeds Q1 expectations, eyes industry growth amidst challenges

Humana's strong Q1 performance and strategic decisions position it well for growth
Challenges like rate disruptions and Medicaid redeterminations require close monitoring
Opportunities in industry growth, member engagement, and benefit enhancements ahead
Commitment to long-term goals and high-quality service evident in company's outlook

Humana meets Q2 expectations, eyes growth in MA platform

Humana's Q2 performance met expectations with a focus on MA platform growth and disciplined investments.
Challenges include higher utilization in Medicare Advantage and broad-based medical cost trends.
Strategic benefits adjustments and competitive positioning present opportunities for growth and margin expansion.
Expectations for 2024 include maintaining market share, offsetting costs, and achieving strong membership growth.

Humana surpasses Q3 earnings expectations, eyes $37 EPS target

Humana's Q3 performance exceeded expectations, with strong membership growth and strategic initiatives driving future profitability.
While facing challenges in benefit ratios and regulatory changes, Humana remains focused on achieving long-term financial targets.
The company's commitment to operational excellence, membership growth, and pricing actions positions it for sustained success.
Strategic partnerships and risk management efforts showcase Humana's resilience and adaptability in a dynamic healthcare landscape.

Humana faces challenges from rising costs but eyes long-term growth

Humana's Q4 2023 earnings call highlighted challenges from increased medical costs and utilization trends impacting financial performance and outlook.
Despite disappointments in short-term results, the company remains confident in the long-term attractiveness of the Medicare Advantage sector.
Strategic efforts to restore margins, address utilization drivers, and engage with providers reflect a proactive approach to managing industry dynamics.
Balancing profitability with membership growth through benefit adjustments and pricing actions is crucial for Humana's sustainable financial performance.

Humana reports solid Q1 performance, eyes margin recovery in 2025

Humana's Q1 2024 earnings call highlighted a strong start to the year, challenges in the industry for 2025, and a focus on margin recovery and growth opportunities. The company remains confident in its outlook, emphasizing pricing discipline and maintaining a strong value proposition in the market.

Humana surpasses Q2 expectations, addresses cost pressures for growth

Humana's Q2 2024 performance exceeded expectations, driven by strong Medicare business and growth in Medicaid and primary care segments.
Challenges such as medical cost pressures were addressed through mitigation measures, while opportunities lie in strategic initiatives and long-term planning.
The company's focus on value, disciplined cost management, and operational efficiency position it well for sustained growth and value creation.

Humana surpasses Q3 expectations, eyes growth through efficiency and investments

Humana's Q3 performance exceeded expectations, with a focus on balancing earnings and investments. The company is strategically positioned to drive growth through membership expansion and operational efficiency. Challenges include managing costs and understanding market dynamics, with opportunities in improving Stars ratings and expanding senior care services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Health insurer Humana announced a succession plan for long-time chief executive officer Bruce Broussard who will retire next year and be replaced by Jim Rechtin, the current CEO of Envision Healthcare.

Humana Sets Succession For Retiring CEO Bruce Broussard

Humana CEO Bruce Broussard will step down in the second half of 2024 after more than a decade at the helm, the insurer said on Wednesday and named healthcare veteran Jim Rechtin as his successor.

Insurer Humana's longtime CEO Broussard to step down next year

Shares of Humana Inc. HUM, -0.23% slipped 0.5% in premarket trading Wednesday, after the health insurer said Chief Executive Bruce Broussard will step down from the role in the “latter half” of 2024, after about 11 years in the role. The company said it named Jim Rechtin as chief operator officer, effective Jan. 8, 2024, as part of a “long-planned CEO transition.

Humana CEO Broussard to step down next year after 11 years in the role, and stock slips

LOUISVILLE, Ky.--(BUSINESS WIRE)--Leading health insurer and health care services company Humana Inc. (NYSE: HUM) announced today it has named health care industry veteran Jim Rechtin as President and Chief Operating Officer of Humana Inc., effective January 8, 2024, as part of a long-planned CEO transition. He will report to Bruce Broussard, CEO, until the latter half of 2024 at which time Broussard will step down and Rechtin will assume the CEO role. Broussard joined Humana in 2011 and assume.

Humana Announces Leadership Transition Plan: Jim Rechtin named Chief Operating Officer and CEO Successor, Bruce Broussard to step down as CEO in the second half of 2024

Humana (HUM) concluded the recent trading session at $501.54, signifying a +0.68% move from its prior day's close.

Humana (HUM) Surpasses Market Returns: Some Facts Worth Knowing

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) will release its financial results for the third quarter 2023 (3Q23) on Wednesday, November 1, 2023, at 6:30 a.m. Eastern time. The company will host a conference call at 9:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2023. To participate via telephone, please register in advance using this link, https://register.vevent.com/register/BId758ed43d68741ac92865ada642803d4. Upon r.

Humana Inc. to Release Third Quarter 2023 Results on November 1, 2023

Humana gets a Buy rating, agreeing with the bullish consensus from analysts, Wall Street, and the quant system. Bullish sentiment fueled by low valuation, cheap share price, dividend stability, profitability on a YoY basis, and positive cash flow. An offsetting issue is HUM stock's underperformance vs. the S&P 500 index for an extended period.

Humana: Bullish Rating Thanks To Strong Financials And Low Valuation

Humana (HUM) enters into a deal with Denver Health to expand its local provider network across the Denver area as well as offer greater care access to its Medicare Advantage members of the region.

Humana (HUM) Boosts Healthcare Choices for MA Members in Denver

Humana has generated positive earnings over the last 6 to 7 years, even during the COVID-19 period. The balance sheet is strong with low debt levels, and the company is strongly cash flow positive. Based on analysts' consensus estimates and conservative multiples, share price growth can be expected to result in solid returns, buying and holding through the end of 2025.

Humana: Upgrade To Buy

Humana (HUM) benefits from an upgraded health plan offering suite, expanding Medicare Advantage membership and solid cash reserves.

Here's Why Investors Should Retain Humana (HUM) Stock Now

DENVER--(BUSINESS WIRE)--Humana and Denver Health sign agreement to expand Humana's Medicare Advantage provider network in the Denver area.

Humana and Denver Health Sign Agreement to Expand Humana's Medicare Advantage Provider Network in the Denver Area

Humana (HUM) aims to expand the reach of its Medicare plans across newer U.S. counties in 2024 through integrating multiple lucrative benefits within them.

Humana's (HUM) 2024 MA Plans Promise a Wider Set of Benefits

TAMPA, Fla.--(BUSINESS WIRE)--Humana ranked #1 in customer satisfaction among Medicare Advantage plans in Florida in J.D. Power 2023 U.S. Medicare Advantage Satisfaction Study.

Humana #1 in Customer Satisfaction Among Medicare Advantage Plans in Florida

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana's 2024 Medicare Advantage health plan offerings are designed with affordability and customer feedback in mind.

Humana's 2024 Medicare Advantage Health Plan Offerings Designed With Affordability, Customer Feedback in Mind

OLDWICK, N.J.--(BUSINESS WIRE)-- #insurance--AM Best has upgraded the Financial Strength Rating (FSR) to A (Excellent) from A- (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) to “a” (Excellent) from “a-” (Excellent) for the health and dental insurance subsidiaries of Humana Inc. (Humana) (headquartered in Louisville, KY) [NYSE: HUM]. These subsidiaries collectively are referred to as Humana Health Group. Concurrently, AM Best has upgraded the Long-Term ICR to “bbb” (Good) from “bbb-” (G.

AM Best Upgrades Credit Ratings of Humana Inc. and Most of Its Health Insurance Subsidiaries

Centene

CVS Health

Elevance Health Inc

UnitedHealth Group

Health insurer UnitedHealth Group Inc. NYSE: UNH has a market capitalization of $466.61 billion, ranking it as the tenth largest company in the S&P 500.

Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?

We believe Humana stock (NYSE: HUM) is a better pick than CSX stock (NYSE: CSX), given its better prospects.

Should You Pick Humana Over CSX Stock For The Next Three Years?

Humana's adjusted diluted EPS and free cash flow payout ratios make the dividend very secure. The managed care company's revenue and adjusted diluted EPS both surged in the first half of 2023. Humana's interest coverage ratio of over 13 is part of why it earns investment-grade credit ratings from the major rating agencies.

Humana: Buy This Amazing Wealth Compounder Now, You'll Be Glad You Did

Johnson & Johnson

Transmedics Group Inc

In the ever-evolving landscape of investing, the spotlight is on the top healthcare stocks to buy on the dip. The healthcare sector is highly known for its robust resilience and incredible growth potential.

Buy the Dip: 3 Healthcare Stocks to Snag Now for Supercharged Gains

Danaher

Medtronic

Healthcare is a sector that has underperformed the broader stock market this year. The S&P 500 Health Care Sector Index is down over 2.50% year-to-date versus a 17% gain in the benchmark S&P 500 index.

The 3 Most Undervalued Healthcare Stocks to Buy in September 2023

WASHINGTON--(BUSINESS WIRE)--The Trust for the National Mall in partnership with Humana (NYSE: HUM) announced today that they will introduce America's newest and most accessible pastime—pickleball—to America's most inviting front yard—the National Mall—with the inaugural National Mall of Pickleball. The National Mall is an iconic open space where for over 100 years, Americans have gathered to play, learn, dream, and connect across cultures and generations. This year, from September 28th through.

Trust for the National Mall and Humana Bring Pickleball to America's Front Yard

The National Mall of Pickleball Will Deliver 180 Hours of Free Court Time for Nearly 800 Picklers Across All Skills and Abilities to Play and Connect in This Iconic Location

COLLEGE STATION, Texas--(BUSINESS WIRE)--Texas A&M University Mays Business School and Humana kick off seventh annual healthcare analytics case competition.

Texas A&M University Mays Business School and Humana Kick Off Seventh Annual Healthcare Analytics Case Competition

Humana (HUM) remains well-poised for growth on the back of an expanding Medicare Advantage membership, upgraded health plan offering suite and solid cash reserves.

Here's Why Investors Should Hold Humana (HUM) in Portfolio

Humana (HUM) enhances its CenterWell brand with the launch of Primary Care Anywhere.

News for Humana Stock (HUM)